Financial Data and Key Metrics Changes - In 2025, the company's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [7][18] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [8][25] - The fourth quarter revenue was RMB 21 billion, reflecting a year-over-year increase of 27.4% [7][18] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, up 24.8% year-over-year, accounting for 82.9% of total revenue [19] - Service revenue increased to RMB 12.6 billion, up 34.1% year-over-year, representing 17.1% of total revenue [19] - The company introduced over 100 new drugs in 2025, a significant increase from 13 in 2024 [8] Market Data and Key Metrics Changes - The annual active user accounts reached approximately 220 million, with an addition of 34 million compared to the previous year [18] - The company established over 300 self-operated pharmacies nationwide, integrating them with on-demand retail services [12] Company Strategy and Development Direction - The company aims to deepen its presence in key healthcare segments through an omnichannel approach and AI-powered healthcare services [6] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the user experience through innovative health solutions [9][15] - The company plans to leverage its supply chain strengths and direct sales capabilities to maintain leadership in the healthcare retail market [15] Management Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a large market size of RMB 3 trillion-4 trillion for the pharmaceutical sector [30] - The company is committed to enhancing user experiences and improving cost efficiency through AI technologies [26] - Management highlighted the importance of a steady and cautious approach to offline business expansion, emphasizing the integration of AI in healthcare services [49] Other Important Information - The company achieved a growth margin of 24.8% in 2025, up 1.9 percentage points year-over-year [22] - The fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained flat at 5.2% [23] - Cash flow from operating activities reached RMB 10.2 billion for the full year [25] Q&A Session Summary Question: Near term and three-year middle term prospects - Management indicated that the pharmaceutical sector, health products, and medical devices present significant growth opportunities, with plans to deepen engagement with pharmaceutical companies and enhance product offerings [29][30][34] Question: Competition landscape - Management expressed confidence in the company's ability to stand out among competitors by leveraging supply chain management and maintaining high product quality [40][41] Question: Plans for brick-and-mortar stores and M&A - Management clarified that there are no plans for large-scale M&A but emphasized the importance of offline practices and the integration of pharmacies to enhance user experiences [43][44][46]

Financial Data and Key Metrics Changes - In 2025, JD Health's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [4][15] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [5][21] - The fourth quarter revenue was RMB 21 billion, a 27.4% increase year-over-year, with net profit of RMB 1.1 billion, up 13.5% year-over-year [4][15] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, up 24.8% year-over-year, accounting for 82.9% of total revenue [16] - Service revenue increased to RMB 12.6 billion, up 34.1% year-over-year, accounting for 17.1% of total revenue [16] - The company introduced over 100 new drugs during the year, a significant increase from 13 in 2024 [5] Market Data and Key Metrics Changes - JD Health's annual active user accounts reached approximately 220 million, with an addition of 34 million compared to the previous year [15] - The healthcare market size is estimated to be around RMB 3 trillion to 4 trillion, indicating significant growth potential for JD Health [24] Company Strategy and Development Direction - JD Health aims to deepen its presence across key healthcare segments through an omnichannel approach and AI-powered healthcare services [4] - The company is committed to enhancing user experience and cost efficiency by leveraging AI technologies in healthcare services [12][20] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the product portfolio, particularly in innovative drugs and health supplements [26][27] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a strong market position and ongoing improvements in operational efficiency [22][31] - The company plans to continue investing in AI technologies and expanding its healthcare service offerings to meet evolving market demands [20][44] Other Important Information - JD Health's fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained stable at 5.2% [19] - The company established over 300 self-operated pharmacies nationwide, integrating them with its on-demand retail business [10] Q&A Session Summary Question: Near term and three-year middle term prospects - Management highlighted the growth potential in the pharmaceutical sector and the need to deepen user engagement and product offerings [23][24] Question: Competition landscape - Management emphasized JD Health's strengths in supply chain management and product quality as key differentiators in a competitive market [31][32] Question: Plans for brick-and-mortar stores and M&A - Management stated there are no plans for large-scale M&A but will continue to develop offline pharmacies to enhance service delivery [33][36]